Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/C3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/C3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/C3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/C3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/C3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/C3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/C3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/C3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00329464 | Oral cavity | EOLP | positive regulation of mononuclear cell proliferation | 27/2218 | 138/18723 | 5.80e-03 | 2.94e-02 | 27 |
GO:005507624 | Oral cavity | EOLP | transition metal ion homeostasis | 27/2218 | 138/18723 | 5.80e-03 | 2.94e-02 | 27 |
GO:00508543 | Oral cavity | EOLP | regulation of antigen receptor-mediated signaling pathway | 15/2218 | 63/18723 | 5.86e-03 | 2.96e-02 | 15 |
GO:000636821 | Oral cavity | EOLP | transcription elongation from RNA polymerase II promoter | 16/2218 | 69/18723 | 5.92e-03 | 2.98e-02 | 16 |
GO:00395354 | Oral cavity | EOLP | regulation of RIG-I signaling pathway | 7/2218 | 20/18723 | 6.20e-03 | 3.09e-02 | 7 |
GO:007124322 | Oral cavity | EOLP | cellular response to arsenic-containing substance | 7/2218 | 20/18723 | 6.20e-03 | 3.09e-02 | 7 |
GO:0048147 | Oral cavity | EOLP | negative regulation of fibroblast proliferation | 9/2218 | 30/18723 | 6.33e-03 | 3.13e-02 | 9 |
GO:000931423 | Oral cavity | EOLP | response to radiation | 72/2218 | 456/18723 | 6.60e-03 | 3.23e-02 | 72 |
GO:000756521 | Oral cavity | EOLP | female pregnancy | 35/2218 | 193/18723 | 6.67e-03 | 3.26e-02 | 35 |
GO:00024604 | Oral cavity | EOLP | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 58/2218 | 356/18723 | 7.27e-03 | 3.52e-02 | 58 |
GO:00512385 | Oral cavity | EOLP | sequestering of metal ion | 6/2218 | 16/18723 | 7.66e-03 | 3.66e-02 | 6 |
GO:006000913 | Oral cavity | EOLP | Sertoli cell development | 5/2218 | 12/18723 | 8.97e-03 | 4.12e-02 | 5 |
GO:001921614 | Oral cavity | EOLP | regulation of lipid metabolic process | 54/2218 | 331/18723 | 9.09e-03 | 4.15e-02 | 54 |
GO:00725032 | Oral cavity | EOLP | cellular divalent inorganic cation homeostasis | 75/2218 | 486/18723 | 9.77e-03 | 4.42e-02 | 75 |
GO:00105866 | Oral cavity | EOLP | miRNA metabolic process | 8/2218 | 27/18723 | 1.07e-02 | 4.75e-02 | 8 |
GO:003952912 | Oral cavity | EOLP | RIG-I signaling pathway | 8/2218 | 27/18723 | 1.07e-02 | 4.75e-02 | 8 |
GO:0060761 | Oral cavity | EOLP | negative regulation of response to cytokine stimulus | 18/2218 | 86/18723 | 1.11e-02 | 4.88e-02 | 18 |
GO:190331133 | Oral cavity | NEOLP | regulation of mRNA metabolic process | 91/2005 | 288/18723 | 2.65e-22 | 7.88e-19 | 91 |
GO:004348434 | Oral cavity | NEOLP | regulation of RNA splicing | 61/2005 | 148/18723 | 5.56e-22 | 1.10e-18 | 61 |
GO:005068433 | Oral cavity | NEOLP | regulation of mRNA processing | 56/2005 | 137/18723 | 4.37e-20 | 6.48e-17 | 56 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C3 | SNV | Missense_Mutation | novel | c.2800N>C | p.Glu934Gln | p.E934Q | P01024 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
C3 | SNV | Missense_Mutation | | c.1052C>T | p.Ser351Phe | p.S351F | P01024 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
C3 | SNV | Missense_Mutation | rs199911426 | c.4594N>T | p.Arg1532Trp | p.R1532W | P01024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
C3 | SNV | Missense_Mutation | | c.4276N>A | p.Asp1426Asn | p.D1426N | P01024 | protein_coding | deleterious(0.01) | probably_damaging(0.929) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C3 | SNV | Missense_Mutation | | c.3803N>G | p.Ser1268Cys | p.S1268C | P01024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
C3 | SNV | Missense_Mutation | | c.1376N>T | p.Ser459Leu | p.S459L | P01024 | protein_coding | tolerated(0.09) | possibly_damaging(0.599) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
C3 | SNV | Missense_Mutation | novel | c.4408N>A | p.Glu1470Lys | p.E1470K | P01024 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C3 | SNV | Missense_Mutation | novel | c.3118G>C | p.Glu1040Gln | p.E1040Q | P01024 | protein_coding | tolerated(0.11) | benign(0.063) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
C3 | SNV | Missense_Mutation | novel | c.2782N>G | p.Ser928Ala | p.S928A | P01024 | protein_coding | tolerated(0.22) | benign(0.007) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
C3 | SNV | Missense_Mutation | | c.1452N>T | p.Glu484Asp | p.E484D | P01024 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | Imprime PGG immunotherapeutic | | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | POT-4 | | 19025129 |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | COMPSTATIN | COMPSTATIN | 25494040 |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | POT-4 | | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | APL-2 | PEGCETACOPLAN | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | clozapine | CLOZAPINE | 26503818 |